Pharmacogenomics polygenic risk score: Ready or not for prime time?

Sonal Singh, Gabriele Stocco, Katherine N. Theken, Alyson Dickson, Qi Ping Feng, Jason H. Karnes, Jonathan D. Mosley, Nihal El Rouby

Research output: Contribution to journalArticlepeer-review

Abstract

Pharmacogenomic Polygenic Risk Scores (PRS) have emerged as a tool to address the polygenic nature of pharmacogenetic phenotypes, increasing the potential to predict drug response. Most pharmacogenomic PRS have been extrapolated from disease-associated variants identified by genome wide association studies (GWAS), although some have begun to utilize genetic variants from pharmacogenomic GWAS. As pharmacogenomic PRS hold the promise of enabling precision medicine, including stratified treatment approaches, it is important to assess the opportunities and challenges presented by the current data. This assessment will help determine how pharmacogenomic PRS can be advanced and transitioned into clinical use. In this review, we present a summary of recent evidence, evaluate the current status, and identify several challenges that have impeded the progress of pharmacogenomic PRS. These challenges include the reliance on extrapolations from disease genetics and limitations inherent to pharmacogenomics research such as low sample sizes, phenotyping inconsistencies, among others. We finally propose recommendations to overcome the challenges and facilitate the clinical implementation. These recommendations include standardizing methodologies for phenotyping, enhancing collaborative efforts, developing new statistical methods to capitalize on drug-specific genetic associations for PRS construction. Additional recommendations include enhancing the infrastructure that can integrate genomic data with clinical predictors, along with implementing user-friendly clinical decision tools, and patient education. Ethical and regulatory considerations should address issues related to patient privacy, informed consent and safe use of PRS. Despite these challenges, ongoing research and large-scale collaboration is likely to advance the field and realize the potential of pharmacogenomic PRS.

Original languageEnglish (US)
Article numbere13893
JournalClinical and Translational Science
Volume17
Issue number8
DOIs
StatePublished - Aug 2024

ASJC Scopus subject areas

  • General Neuroscience
  • General Biochemistry, Genetics and Molecular Biology
  • General Pharmacology, Toxicology and Pharmaceutics

Fingerprint

Dive into the research topics of 'Pharmacogenomics polygenic risk score: Ready or not for prime time?'. Together they form a unique fingerprint.

Cite this